Stereotaxis, Inc. – AMEX:STXS

Stereotaxis stock price today

$2.95
+0.66
+28.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

Stereotaxis stock price monthly change

+20.53%
month

Stereotaxis stock price quarterly change

+20.53%
quarter

Stereotaxis stock price yearly change

+33.14%
year

Stereotaxis key metrics

Market Cap
195.72M
Enterprise value
128.52M
P/E
-6.62
EV/Sales
4.56
EV/EBITDA
-7.25
Price/Sales
4.66
Price/Book
4.98
PEG ratio
0.10
EPS
-0.24
Revenue
27.10M
EBITDA
-20.68M
Income
-20.21M
Revenue Q/Q
5.07%
Revenue Y/Y
-2.00%
Profit margin
-66.18%
Oper. margin
-66.71%
Gross margin
65.62%
EBIT margin
-66.71%
EBITDA margin
-76.33%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Stereotaxis stock price history

Stereotaxis stock forecast

Stereotaxis financial statements

Stereotaxis, Inc. (AMEX:STXS): Profit margin
Jun 2023 7.85M -4.95M -63.07%
Sep 2023 7.79M -5.70M -73.18%
Dec 2023 4.56M -5.04M -110.41%
Mar 2024 6.88M -4.50M -65.51%
Stereotaxis, Inc. (AMEX:STXS): Analyst Estimates
Sep 2025 11.1M -1.65M -14.9%
Oct 2025 11.75M -3.33M -28.42%
Dec 2025 13.85M -3.75M -27.12%
Mar 2026 9.3M -4.13M -44.46%
  • Analysts Price target

  • Financials & Ratios estimates

Stereotaxis, Inc. (AMEX:STXS): Debt to assets
Jun 2023 48315000 21.34M 44.18%
Sep 2023 44528000 20.23M 45.43%
Dec 2023 41909000 19.98M 47.7%
Mar 2024 39452000 19.42M 49.23%
Stereotaxis, Inc. (AMEX:STXS): Cash Flow
Jun 2023 -2.93M 20.12M -26K
Sep 2023 -967K -10K 25K
Dec 2023 -2.43M 0 26K
Mar 2024 -2.34M 0 30K

Stereotaxis alternative data

Stereotaxis, Inc. (AMEX:STXS): Employee count
Aug 2023 130
Sep 2023 130
Oct 2023 130
Nov 2023 130
Dec 2023 130
Jan 2024 130
Feb 2024 130
Mar 2024 122
Apr 2024 122
May 2024 122
Jun 2024 122
Jul 2024 122

Stereotaxis other data

11.57% -35.10%
of STXS is owned by hedge funds
8.80M -26.71M
shares is hold by hedge funds

Stereotaxis, Inc. (AMEX:STXS): Insider trades (number of shares)
Period Buy Sel
Aug 2023 75020 0
Sep 2023 30673 0
Nov 2023 75826 0
Dec 2023 11060 0
May 2024 10026 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ISAAC PAUL J director, other: See Remarks
Common stock 1,000 $1.96 $1,958
Purchase
ISAAC PAUL J director, other: See Remarks
Common stock 3,026 $1.9 $5,746
Purchase
ISAAC PAUL J director, other: See Remarks
Common stock 6,000 $1.91 $11,436
Purchase
ISAAC PAUL J director
Common Stock 11,060 $1.72 $19,023
Purchase
ISAAC PAUL J director
Common Stock 2,808 $1.56 $4,380
Purchase
ISAAC PAUL J director
Common Stock 18 $1.5 $27
Purchase
ISAAC PAUL J director
Common Stock 6,000 $1.53 $9,180
Purchase
ISAAC PAUL J director
Common Stock 6,000 $1.54 $9,240
Purchase
ISAAC PAUL J director
Common Stock 6,000 $1.55 $9,300
Purchase
ISAAC PAUL J director
Common Stock 15,000 $1.51 $22,650
Insider Compensation
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA (1987) Chief Executive Officer & Chairman
$60,030
Monday, 16 December 2024
zacks.com
Monday, 9 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
seekingalpha.com
Tuesday, 26 November 2024
zacks.com
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Monday, 11 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Monday, 9 September 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Sunday, 25 August 2024
seekingalpha.com
Thursday, 15 August 2024
zacks.com
zacks.com
Monday, 12 August 2024
seekingalpha.com
zacks.com
globenewswire.com
globenewswire.com
Monday, 22 July 2024
globenewswire.com
Thursday, 18 July 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
Monday, 27 May 2024
zacks.com
Friday, 24 May 2024
zacks.com
globenewswire.com
Thursday, 23 May 2024
seekingalpha.com
Wednesday, 22 May 2024
globenewswire.com
Wednesday, 15 May 2024
GlobeNewsWire
  • What's the price of Stereotaxis stock today?

    One share of Stereotaxis stock can currently be purchased for approximately $2.95.

  • When is Stereotaxis's next earnings date?

    Unfortunately, Stereotaxis's (STXS) next earnings date is currently unknown.

  • Does Stereotaxis pay dividends?

    No, Stereotaxis does not pay dividends.

  • How much money does Stereotaxis make?

    Stereotaxis has a market capitalization of 195.72M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.89% to 26.77M US dollars.

  • What is Stereotaxis's stock symbol?

    Stereotaxis, Inc. is traded on the AMEX under the ticker symbol "STXS".

  • What is Stereotaxis's primary industry?

    Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.

  • How do i buy shares of Stereotaxis?

    Shares of Stereotaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Stereotaxis's key executives?

    Stereotaxis's management team includes the following people:

    • Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA Chief Executive Officer & Chairman(age: 38, pay: $60,030)
  • How many employees does Stereotaxis have?

    As Jul 2024, Stereotaxis employs 122 workers.

  • When Stereotaxis went public?

    Stereotaxis, Inc. is publicly traded company for more then 21 years since IPO on 12 Aug 2004.

  • What is Stereotaxis's official website?

    The official website for Stereotaxis is stereotaxis.com.

  • Where are Stereotaxis's headquarters?

    Stereotaxis is headquartered at 710 North Tucker Boulevard, Saint Louis, MO.

  • How can i contact Stereotaxis?

    Stereotaxis's mailing address is 710 North Tucker Boulevard, Saint Louis, MO and company can be reached via phone at +31 46786100.

Stereotaxis company profile:

Stereotaxis, Inc.

stereotaxis.com
Exchange:

AMEX

Full time employees:

122

Industry:

Medical - Instruments & Supplies

Sector:

Healthcare

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

710 North Tucker Boulevard
Saint Louis, MO 63101

CIK: 0001289340
ISIN: US85916J4094
CUSIP: 85916J409